What Is This?
In 2010, researchers at the J. Craig Venter Institute announced they had created the first self-replicating synthetic cell — a bacterium whose entire genome was designed on a computer, synthesised from chemical building blocks, and transplanted into an emptied bacterial shell. The cell divided. It was alive. It had no natural ancestor. Its genome contained a watermark, a secret message written in the genetic code by the researchers who designed it.
They called it JCVI-syn1.0. The name was deliberately reminiscent of software versioning. The implication was intentional: DNA can be written like code.
This is the premise of synthetic biology — the discipline that applies engineering principles to living systems. Where genetic engineering (CRISPR and its predecessors) edits existing genetic sequences, synthetic biology designs and builds new ones from scratch. Where biotechnology focuses on what biology can do, synthetic biology asks what biology could do if redesigned with engineering intent.
The field draws on three converging capabilities that matured simultaneously in the 2000s and 2010s:
DNA synthesis: The cost of synthesising a base pair of custom DNA has fallen from roughly $10 in 1990 to approximately $0.001 today — a factor of 10,000 cheaper in 30 years, outpacing even Moore's Law. You can now order custom-designed gene sequences online and receive them within days, as easily as ordering PCR primers.
DNA sequencing: Reading genomes has become fast and cheap enough to treat as routine. You can sequence a full human genome for under $200. Sequencing bacteria, viruses, and model organisms is trivial. This means the "read" side of biology has commoditised, enabling the "write" side to be tested rapidly.
Computational biology and machine learning: Protein folding prediction (AlphaFold), protein design tools (RFdiffusion, ProteinMPNN), and generative models for gene sequences have made it possible to design biological components computationally — to specify what you want a protein to do and have software propose sequences that might do it, without requiring the laborious trial-and-error of traditional molecular biology.
What you can build:
Metabolic engineering — Reprogramming cells to produce specific molecules. E. coli that produces human insulin (since 1982 — this is the oldest commercial synthetic biology application). Yeast that produces artemisinin (antimalarial drug that previously required extensive harvesting of the sweet wormwood plant). Microorganisms engineered to produce spider silk proteins (stronger than steel by weight). Bacteria engineered to produce biofuels from agricultural waste.
Genetic circuits — Biological equivalents of electronic circuits: regulatory genes that act as AND gates, OR gates, feedback loops, timers, and switches. These can make cells respond to specific signals with specific outputs — a cell that detects a cancer biomarker and produces a therapeutic protein in response, or a cell that glows in the presence of a specific toxin.
Programmable organisms — E. coli engineered with an expanded genetic code (additional synthetic amino acids) that can produce proteins no natural organism can make, with novel chemical properties. Organisms with "recoded genomes" where standard codons are reassigned, making them resistant to viral infection.
Cell-free systems — Biological manufacturing that uses the cellular machinery without the cell itself: cell-free expression systems that produce proteins and molecules in a test tube from engineered genetic instructions, without requiring living organisms at all.^1
Why Does It Matter?
- It's building toward biology as a general manufacturing platform. The hypothesis: for many classes of molecules and materials, engineered biology will be cheaper, more sustainable, and more precisely controllable than chemical synthesis. Insulin, vaccines, growth hormones, and many cancer drugs are already manufactured biologically. The extension is to commodity materials: plastics, textiles, dyes, food ingredients, fragrances, construction materials. Bolt Threads has produced spider silk proteins at commercial scale. Ginkgo Bioworks operates what they describe as a "cell programming platform" — foundry infrastructure for engineering microorganisms to specification, in the same way that semiconductor foundries manufacture chips to specification. The economics of biological manufacturing improve with scale and automation in ways that make the comparison to semiconductor fabrication apt.^2
- AlphaFold's protein structure database is the pivotal enabling unlock. When DeepMind released structures for over 200 million proteins in 2022, they effectively gave synthetic biologists a reference library for understanding and designing proteins that had previously required years of experimental work per protein. Coupled with generative protein design tools (which can now design novel proteins with specified functions from scratch), this has compressed timelines for developing new enzymes, therapeutics, and biological components by factors of 10-100x. The protein design revolution is the AlphaFold story's practical downstream.^3
- Cellular agriculture is the application most people don't realise is already commercial. Cultivated meat — meat grown from animal cells without slaughtering an animal — is the poster child, but the more immediately scalable applications are precision fermentation for dairy proteins (Perfect Day, which produces whey proteins identical to cow's milk from engineered yeast) and egg proteins. These products are in commercial distribution. The cost curves are following the DNA synthesis cost curve — down by factors of 10 every 5-7 years. The question is not whether cell-based and fermentation-based food production will be cost-competitive with conventional agriculture, but when.^4
- The biosecurity risk is the inverse of the opportunity. The same capabilities that enable engineered therapies and sustainable materials also lower the barrier to engineering pathogens. This is the field's defining dual-use tension. The synthesis of the 1918 influenza virus was published in Science in 2005 — a legitimate scientific achievement that also constituted a roadmap for anyone wanting to recreate it. CRISPR's accessibility means gene editing capability has diffused far beyond the controlled environments of major research institutions. The governance frameworks for this technology are significantly behind the technical capabilities, and the asymmetry (defenders must prevent all attacks; attackers need succeed only once) is acute.
- The platform company model — biology as infrastructure — is the most interesting business structure. Ginkgo Bioworks went public in 2021 with the thesis of being the AWS of synthetic biology: provide the foundry, the tooling, and the expertise for others to build on, rather than betting on specific applications. The model is early and the path to profitability has been difficult, but the concept is sound. The most defensible position in synthetic biology is the platform and tools layer — DNA synthesis companies, protein design software, cell line repositories, automation — rather than any specific product application, which can be commodity-priced or competed away.
Key People & Players
J. Craig Venter — Sequenced the first human genome (privately, in competition with the public Human Genome Project), founded the J. Craig Venter Institute, and created the first synthetic cell. More entrepreneur than scientist; his career is a series of large, aggressive bets on the future of biological engineering. His current company, Human Longevity Inc., is applying synthetic biology methods to healthspan extension.^5
George Church (Harvard/MIT Wyss Institute) — One of the most prolific and imaginative figures in synthetic biology. His work spans synthetic genome design, recoded organisms, gene therapy, and de-extinction (the Colossal Biosciences woolly mammoth revival is partly built on his lab's work). He is simultaneously one of the most visionary and the most biosecurity-controversial figures in the field.
Drew Endy (Stanford) — Co-founder of the iGEM (International Genetically Engineered Machine) Foundation, which runs an annual competition for synthetic biology teams, and one of the clearest thinkers about both the opportunity and the ethics of biological engineering. His "BioBricks" standard for modular genetic parts was the field's first attempt at component standardisation.
Jason Kelly (Ginkgo Bioworks) — Built the largest synthetic biology platform company. Ginkgo's model — foundry infrastructure for engineering organisms to customer specifications — is the bet that biology becomes a programmable manufacturing substrate that requires industrial-scale infrastructure to operate efficiently.
Frances Arnold (Caltech) — Nobel Laureate 2018 for directed evolution — a technique for rapidly evolving proteins with desired properties through iterative rounds of mutation and selection. Directed evolution and computational protein design are the two primary routes to novel enzymes, and Arnold's approach has produced industrial enzymes used in manufacturing, pharmaceuticals, and biofuels at commercial scale.
The Current State
Synthetic biology is in the transition from proof-of-concept to early commercialisation. A handful of applications are commercially mature (insulin, artemisinin, certain industrial enzymes). A larger set are in commercial development with early market entry (cultivated proteins, spider silk materials, engineered yeast for fragrance and food ingredients). The majority of the anticipated applications (programmable medicines, large-scale biomanufacturing, agricultural biological inputs) are 5-15 years from significant commercial scale.
The cost curves are the leading indicator. DNA synthesis costs dropping below $0.001/bp is making genome-scale design economically feasible. Protein design tools are compressing experimental development timelines. Automated biofoundry infrastructure (robotic lab systems that run thousands of experimental variants simultaneously) is taking the bottleneck from design to testing throughput.
The regulatory environment is the friction layer. Approval pathways for engineered organisms in food, agriculture, and therapeutics are designed for traditional biotechnology — they were not written for organisms designed from first principles on computers. Regulatory timelines of 7-15 years for agricultural applications are a significant constraint. Ginkgo and others are investing in regulatory engagement as explicitly as in technology development.
What to watch: The intersection of AI and synthetic biology — AI-designed protein sequences, AI-predicted metabolic pathway engineering, AI-optimised fermentation conditions — is moving faster than any other frontier in the field. The AlphaFold → RFdiffusion → protein design pipeline has essentially solved the protein structure prediction problem and is rapidly eroding the protein design problem. The next 5 years will determine how quickly this translates into novel therapeutics and biological materials at commercial scale.
Best Resources to Learn More
- A Crack in Creation by Jennifer Doudna (2017) — Co-discoverer of CRISPR, on the technology and its implications. The best accessible treatment of where gene editing fits in the broader synthetic biology story.^6
- Regenesis by George Church & Ed Regis (2012) — The most visionary treatment of what synthetic biology could achieve, from one of its most ambitious practitioners.^7
- Ginkgo Bioworks: Cell programming platform — The commercial infrastructure of the field.^8
- The Code Breaker by Walter Isaacson (2021) — Narrative history of CRISPR's development and the people behind it. Excellent entry-level reading.^9
- iGEM Foundation — The annual synthetic biology competition has produced some of the field's most creative work. The project registry is a window into the breadth of active applications.^10